Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy of Empagliflozin in Hemodialysis
Sponsor: NYU Langone Health
Summary
A 12-week, phase II, randomized, double-blind, placebo-controlled, multi-center study to assess the safety, tolerability, and preliminary efficacy of empagliflozin versus placebo among patients initiating hemodialysis (n=60) for the treatment of end-stage kidney disease.
Official title: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Empagliflozin Among Patients Initiating Hemodialysis for the Treatment of End-Stage Kidney Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2024-01-31
Completion Date
2026-12-30
Last Updated
2025-12-04
Healthy Volunteers
No
Conditions
Interventions
Empagliflozin 10 MG
Sodium glucose cotransporter 2 inhibitor (SGLT2i) dosed once-daily over 12 weeks. Administered as oral tablet.
Placebo
Empagliflozin-matching placebo dosed once-daily over 12 weeks. Administered as oral tablet.
Locations (2)
Brigham and Women's Hospital
Boston, Massachusetts, United States
NYU Langone Health
New York, New York, United States